News | November 09, 2023
Bayer posts Q3 2023 Group sales Euro 10.34 billion
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
This product will be manufactured at Lupin’s Pithampur facility in India
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Subscribe To Our Newsletter & Stay Updated
